KeyCorp Reaffirms “Hold” Rating for DaVita HealthCare Partners Inc. (DVA)

DaVita HealthCare Partners Inc. (NYSE:DVA)‘s stock had its “hold” rating restated by stock analysts at KeyCorp in a note issued to investors on Monday.

DVA has been the subject of a number of other reports. BidaskClub downgraded shares of DaVita HealthCare Partners from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. SunTrust Banks, Inc. set a $57.00 price objective on shares of DaVita HealthCare Partners and gave the stock a “hold” rating in a research report on Sunday, October 15th. Royal Bank Of Canada reduced their price objective on shares of DaVita HealthCare Partners from $64.00 to $60.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 8th. Wolfe Research raised shares of DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating in a research report on Monday, October 23rd. Finally, J P Morgan Chase & Co downgraded shares of DaVita HealthCare Partners from a “neutral” rating to an “underweight” rating in a research report on Monday, October 9th. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $63.00.

Shares of DaVita HealthCare Partners (NYSE:DVA) opened at $54.99 on Monday. DaVita HealthCare Partners has a 52-week low of $52.51 and a 52-week high of $70.16. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.40 and a quick ratio of 1.35. The stock has a market cap of $10,407.74, a PE ratio of 15.71, a price-to-earnings-growth ratio of 11.05 and a beta of 0.98.

DaVita HealthCare Partners (NYSE:DVA) last issued its quarterly earnings data on Tuesday, November 7th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.94 by ($0.13). DaVita HealthCare Partners had a return on equity of 13.31% and a net margin of 3.40%. The firm had revenue of $3.92 billion during the quarter, compared to the consensus estimate of $3.91 billion. During the same period in the previous year, the company posted $0.95 earnings per share. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. equities analysts predict that DaVita HealthCare Partners will post 3.43 earnings per share for the current fiscal year.

DaVita HealthCare Partners declared that its board has authorized a share buyback plan on Tuesday, October 10th that authorizes the company to buyback $1.50 billion in shares. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/11/14/keycorp-reaffirms-hold-rating-for-davita-healthcare-partners-inc-dva.html.

Several institutional investors have recently added to or reduced their stakes in DVA. Thrivent Financial For Lutherans grew its position in shares of DaVita HealthCare Partners by 4.4% during the 1st quarter. Thrivent Financial For Lutherans now owns 5,730 shares of the company’s stock valued at $389,000 after acquiring an additional 240 shares during the period. Mn Services Vermogensbeheer B.V. lifted its stake in shares of DaVita HealthCare Partners by 491.6% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 25,274 shares of the company’s stock valued at $1,637,000 after buying an additional 21,002 shares in the last quarter. Eqis Capital Management Inc. lifted its stake in shares of DaVita HealthCare Partners by 2.2% during the 2nd quarter. Eqis Capital Management Inc. now owns 4,600 shares of the company’s stock valued at $298,000 after buying an additional 100 shares in the last quarter. Founders Capital Management LLC lifted its stake in shares of DaVita HealthCare Partners by 0.6% during the 2nd quarter. Founders Capital Management LLC now owns 93,824 shares of the company’s stock valued at $6,076,000 after buying an additional 520 shares in the last quarter. Finally, PGGM Investments purchased a new stake in shares of DaVita HealthCare Partners during the 2nd quarter valued at approximately $28,598,000. 84.73% of the stock is owned by hedge funds and other institutional investors.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply